• A conference call in French with the Company’s Executive Management is planned for Wednesday January 25, 2017 at 6 PM (CET)
• A conference call in English is scheduled on Wednesday January 25, 2017 at 7:30 PM (CET)
Lyon, France, January 25, 2017 - Adocia (Euronext Paris : FR0011184241 - ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, invites you to a presentation to update its programs.
« In light of the reaction of the marketplace, we intend to provide an update on our ongoing projects in order to clarify the contents of our press release issued last week. » said Gérard Soula, Chairman and CEO.
Given its €58 million cash position at the beginning of 2017 and current market conditions, Adocia would like to clarify that no capital increase is being considered.
Wednesday January 25, 2017 at 6:00 pm (CET) - Conference call in French
Dial-in number for France: +33 1 70 77 09 26
Wednesday January 25, 2017 at 7:30 pm (CET) - Conference call in English
Dial-in number for UK: ++44 203 04 32 439
Dial-in number for the US: +1 646 722 49 08
www.adocia.com
The following members of Adocia leadership team will conduct the call:
• Gérard Soula, President and CEO
• Olivier Soula, R&D Director & Deputy General Manager
• Valérie Danaguezian, CFO
• Rémi Soula, Director of Business Development & Intellectual Property
About ADOCIA
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry.
The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.
Adocia’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Adocia is also developing an aqueous formulation of human glucagon (BioChaperone Human Glucagon), two combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), two combinations of insulin lispro with synergistic prandial hormones (BioChaperone Lispro Pramlintide and BioChaperone Lispro Exenatide), and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development. In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro projects.
Adocia aims to deliver “Innovative medicine for everyone, everywhere.”
To learn more about Adocia, please visit us at www.adocia.com
